The Cannabinoid Receptor-1 Antagonist Rimonabant Inhibits Platelet Activation and Reduces Pro-inflammatory Chemokines and Leukocytes in Zucker Rats

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2008 May 13

PMID 18469848

Citations 26

Authors

A Schafer

J Pfrang

J Neumuller

S Fiedler

G Ertl

J Bauersachs

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: We investigated the effect of rimonabant on inflammation and enhanced platelet reactivity in type 2 diabetic Zucker rats, an experimental model of impaired glucose tolerance and the metabolic syndrome.

Experimental Approach: Rimonabant (10 mg kg(-1) by gavage) was fed for 2 weeks to 3-month-old male obese Zucker rats as an impaired glucose tolerance model and for 10 weeks to 6-month-old male obese Zucker rats as a model of the metabolic syndrome. RANTES (Regulated upon Activation, Normal T cell Expressed, and Secreted) and MCP-1 (monocyte chemotactic protein-1) serum levels were determined by ELISA. Leukocyte populations were quantitatively assessed using a veterinary differential blood cell counter. Platelet activation was assessed by flow-cytometry, platelet aggregation, and adhesion of isolated platelets to immobilized fibrinogen.

Key Results: RANTES and MCP-1 serum levels were increased in obese vs lean Zucker rats and significantly reduced by long-term treatment with rimonabant, which slowed weight gain in rats with the metabolic syndrome. Neutrophils and monocytes were significantly increased in young and old obese vs lean Zucker rats and lowered by rimonabant. Platelet-bound fibrinogen was significantly enhanced in obese vs lean Zucker rats of both age, and was reduced by rimonabant. Platelets from obese rats were more sensitive to thrombin-induced aggregation and adhesion to fibrinogen, which were both attenuated by rimonabant therapy.

Conclusions And Implications: We demonstrate positive modulation of circulating neutrophil and monocyte numbers, reduced platelet activation and lower RANTES and MCP-1 levels by rimonabant in Zucker rats. This may potentially contribute to a reduction of cardiovascular risk.

Citing Articles

Female and male obese Zucker rats display differential inflammatory mediator and long non-coding RNA profiles.

Patel N, Lui A, Trujillo A, Motawe Z, Bader D, Schuster J Life Sci. 2023; 335:122285.

PMID: 37995934 PMC: 10760426. DOI: 10.1016/j.lfs.2023.122285.

Pharmacognosy and Effects of Cannabinoids in the Vascular System.

Mensah E, Tabrizchi R, Daneshtalab N ACS Pharmacol Transl Sci. 2022; 5(11):1034-1049.

PMID: 36407955 PMC: 9667477. DOI: 10.1021/acsptsci.2c00141.

Role of microRNA in CB1 antagonist-mediated regulation of adipose tissue macrophage polarization and chemotaxis during diet-induced obesity.

Mehrpouya-Bahrami P, Miranda K, Singh N, Zumbrun E, Nagarkatti M, Nagarkatti P J Biol Chem. 2019; 294(19):7669-7681.

PMID: 30910812 PMC: 6514622. DOI: 10.1074/jbc.RA118.005094.

Orphan nuclear receptor ERRγ is a key regulator of human fibrinogen gene expression.

Zhang Y, Kim D, Lu Y, Jung Y, Lee J, Kim Y PLoS One. 2017; 12(7):e0182141.

PMID: 28750085 PMC: 5531639. DOI: 10.1371/journal.pone.0182141.

Developmental Role of Macrophage Cannabinoid-1 Receptor Signaling in Type 2 Diabetes.

Jourdan T, Szanda G, Cinar R, Godlewski G, Holovac D, Park J Diabetes. 2017; 66(4):994-1007.

PMID: 28082458 PMC: 5360301. DOI: 10.2337/db16-1199.

References

Schafer A, Alp N, Cai S, Lygate C, Neubauer S, Eigenthaler M . Reduced vascular NO bioavailability in diabetes increases platelet activation in vivo. Arterioscler Thromb Vasc Biol. 2004; 24(9):1720-6. DOI: 10.1161/01.ATV.0000138072.76902.dd. View

Henness S, Robinson D, Lyseng-Williamson K . Rimonabant. Drugs. 2006; 66(16):2109-19. DOI: 10.2165/00003495-200666160-00006. View

Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I . A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med. 2002; 196(7):887-96. PMC: 2194025. DOI: 10.1084/jem.20012044. View

Schafer A, Widder J, Eigenthaler M, Bischoff H, Ertl G, Bauersachs J . Increased platelet activation in young Zucker rats with impaired glucose tolerance is improved by acarbose. Thromb Haemost. 2004; 92(1):97-103. DOI: 10.1160/TH04-02-0118. View

Sjostrom L, Narbro K, Sjostrom C, Karason K, Larsson B, Wedel H . Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007; 357(8):741-52. DOI: 10.1056/NEJMoa066254. View

Gawaz M, Langer H, May A . Platelets in inflammation and atherogenesis. J Clin Invest. 2005; 115(12):3378-84. PMC: 1297269. DOI: 10.1172/JCI27196. View

Despres J, Golay A, Sjostrom L . Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005; 353(20):2121-34. DOI: 10.1056/NEJMoa044537. View

Hansson G . Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352(16):1685-95. DOI: 10.1056/NEJMra043430. View

Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Liaudet L, Huffman J . CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol. 2007; 293(4):H2210-8. PMC: 2229632. DOI: 10.1152/ajpheart.00688.2007. View

10.

Veillard N, Kwak B, Pelli G, Mulhaupt F, James R, Proudfoot A . Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res. 2003; 94(2):253-61. DOI: 10.1161/01.RES.0000109793.17591.4E. View

11.

Poirier B, Bidouard J, Cadrouvele C, Marniquet X, Staels B, OConnor S . The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab. 2005; 7(1):65-72. DOI: 10.1111/j.1463-1326.2004.00374.x. View

12.

Chiasson J, Josse R, Gomis R, Hanefeld M, Karasik A, Laakso M . Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003; 290(4):486-94. DOI: 10.1001/jama.290.4.486. View

13.

Schafer A, Fraccarollo D, Vogt C, Flierl U, Hemberger M, Tas P . Improved endothelial function and reduced platelet activation by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with streptozotocin-induced diabetes mellitus. Biochem Pharmacol. 2007; 73(9):1367-75. DOI: 10.1016/j.bcp.2007.01.013. View

14.

Resnick H, Harris M, Brock D, Harris T . American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2000; 23(2):176-80. DOI: 10.2337/diacare.23.2.176. View

15.

Schulz C, Schafer A, Stolla M, Kerstan S, Lorenz M, von Bruhl M . Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets. Circulation. 2007; 116(7):764-73. DOI: 10.1161/CIRCULATIONAHA.107.695189. View

16.

Schafer A, Flierl U, Kobsar A, Eigenthaler M, Ertl G, Bauersachs J . Soluble guanylyl cyclase activation with HMR1766 attenuates platelet activation in diabetic rats. Arterioscler Thromb Vasc Biol. 2006; 26(12):2813-8. DOI: 10.1161/01.ATV.0000249407.92147.12. View

17.

Murphy N, Macintyre K, Stewart S, Hart C, Hole D, McMurray J . Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15 000 middle-aged men and women (the Renfrew-Paisley study). Eur Heart J. 2005; 27(1):96-106. DOI: 10.1093/eurheartj/ehi506. View

18.

Gawaz M, Neumann F, Dickfeld T, Koch W, Laugwitz K, Adelsberger H . Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation. 1998; 98(12):1164-71. DOI: 10.1161/01.cir.98.12.1164. View

19.

Eriksson E . Mechanisms of leukocyte recruitment to atherosclerotic lesions: future prospects. Curr Opin Lipidol. 2004; 15(5):553-8. DOI: 10.1097/00041433-200410000-00009. View

20.

Sheikine Y, Hansson G . Chemokines as potential therapeutic targets in atherosclerosis. Curr Drug Targets. 2006; 7(1):13-27. DOI: 10.2174/138945006775270240. View